Skip to main content
. 2023 Mar 10;19(3):e1010843. doi: 10.1371/journal.ppat.1010843

Fig 4. ZIKV evades type-I and III IFN antiviral activity post-infection.

Fig 4

A) Timeline for IFN treatment regimes in HTR8 cells, arrows indicate media changes with either untreated media, IFNα, IFNε, or viral inoculum. B & C) HTR8 cells were infected with ZIKV PRVABC59 at a MOI of 1, cells were either primed with the indicated IFN (mIFNε 10 U/mL or hIFNα-2A 500 U/mL) or treated post infection. 48 hpi supernatants and RNA were harvested for determination of infectious virus by Focus Forming Assay or quantification of viral RNA by qRT-PCR. D & E) HTR8 cells were infected with ZIKV PRVABC59 at a MOI of 1, cells were either primed for 24h with hIFN λ-III (100 ng/mL) or treated post 24h post infection. Viral RNA and supernatant were collected 48hpi for determination of infectious virus by Focus Forming Assay or quantification of viral RNA by qRT-PCR. Statistical analyses are performed by or one-way ANOVA compared to the untreated control, (n.s non-significant, * P < 0.05, ** P < 0.01). Data are presented as means +/- S.D. Schematic created with BioRender.com.